Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Updated daily

Drug recalls

Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.

Class ITerminatedJan 2, 2019Phenylephrine HClLabeling: Label Error on Declared Strength: Label incorrectly lists concentration as "10 mcg per mL" rather than the correct concentration of "100 mcg per mL".Advanced Pharma Inc. · D-0347-2019Class IIITerminatedJan 2, 2019Temozolomide CapsulesFailed Dissolution SpecificationsAmerigen Pharmaceuticals Inc. · D-0345-2019Class IIITerminatedJan 2, 2019Temozolomide CapsulesFailed Dissolution SpecificationsAmerigen Pharmaceuticals Inc. · D-0344-2019Class IIITerminatedDec 26, 2018AbsoricaSubpotent Drug: Isotretinoin content results were lower than the specification limit obtained during routing product monitoring.Sun Pharmaceutical Industries, Inc. · D-1207-2019Class IITerminatedDec 26, 2018Nevirapine Extended Release TabletsFailed Dissolution Specifications.Cipla Limited · D-0382-2019Class ITerminatedDec 26, 2018Lubrisine eye dropsLack of Sterility Assurance and Incorrect/Undeclared excipient: Product was found to contain undeclared colloidal silverResults RNA, LLC · D-0360-2019Class ITerminatedDec 26, 2018Dyural-80 Injection KitLabeling: Not eslewhere classified - The kits include Sodium Chloride, USP, 0.9% which was recalled by the manufacturer due to the product insert incorrectly stating...Asclemed USA Inc. dba Enovachem · D-0354-2019Class ITerminatedDec 26, 2018Dyural-40 Injection KitLabeling: Not eslewhere classified - The kits include Sodium Chloride, USP, 0.9% which was recalled by the manufacturer due to the product insert incorrectly stating...Asclemed USA Inc. dba Enovachem · D-0353-2019Class IIITerminatedDec 26, 2018Aprepitant CapsulesShortfill: Aprepitant capsules 40 mg is being recalled due to customer reports of missing capsule in the blister pack.Glenmark Pharmaceuticals Inc., USA · D-0349-2019Class IIITerminatedDec 26, 2018NYSTATIN Oral SuspensionFailed Impurities/Degradation Specifications:Out of specification for impurities.VistaPharm, Inc. · D-0348-2019Class IITerminatedDec 26, 2018Human Chorionic Gonadotropin 3000 IULack of Assurance of Sterility: Inadequate processes and equipment to assure the sterility of products intended to be sterile.Pharm D Solutions, LLC · D-0343-2019Class IIITerminatedDec 26, 2018Options Rx Anti-Oxidant Oil-Free SunscreeenSubpotent Drug:Out of specification for percentage of active pharmaceutical ingredients.CBI Laboratories, Inc. · D-0342-2019Class IIITerminatedDec 26, 2018Advanced Protection Sunscreen spf 30Subpotent Drug:Out of specification for percentage of active pharmaceutical ingredients.CBI Laboratories, Inc. · D-0341-2019Class IITerminatedDec 26, 2018Oxybutynin Chloride TabletsLabeling: Wrong bar codeKVK-Tech, Inc. · D-0340-2019Class IITerminatedDec 26, 2018LevoxylSuperpotent Drug.Pfizer Inc. · D-0339-2019Class IITerminatedDec 26, 2018Monsel'sSuperpotent Drug: contains higher levels of Iron than labeled.Gordon Laboratories · D-0338-2019Class IITerminatedDec 26, 2018Infants' IbuprofenSuperpotent Drug: recalled lots may have higher concentration of ibuprofen.Tris Pharma Inc. · D-0337-2019Class IITerminatedDec 26, 2018Infants' IbuprofenSuperpotent Drug: recalled lots may have higher concentration of ibuprofen.Tris Pharma Inc. · D-0336-2019Class IITerminatedDec 26, 2018infants* IBUPROFENSuperpotent Drug: recalled lots may have higher concentration of ibuprofen.Tris Pharma Inc. · D-0335-2019Class IITerminatedDec 26, 2018Fentanyl Citrate 2 mcg per mLSub-potentPharmedium Services, LLC · D-0334-2019Class IITerminatedDec 26, 2018Fentanyl Citrate 2 mcg per mLSub-potentPharmedium Services, LLC · D-0333-2019Class IITerminatedDec 26, 2018OmnipaqueDefective Container: vial defect was identified that could potentially impact the container closure and result in a lack of sterility assurance and/or the potential for...GE Healthcare Inc. Life Sciences · D-0319-2019Class IITerminatedDec 26, 2018Estradiol TabletsPresence of foreign tablet/capsule: A single foreign tablet was found in pharmacy dispensed bottle of 30 Estradiol 2 mg tablets.Epic Pharma, LLC · D-0297-2019Class IIOngoingDec 19, 2018Valsartan and Hydrochlorothiazide TabletsGCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.Mylan Laboratories Limited, (Nashik FDF) · D-0332-2019Class IIOngoingDec 19, 2018Valsartan and Hydrochlorothiazide TabletsGCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.Mylan Laboratories Limited, (Nashik FDF) · D-0331-2019Class IIOngoingDec 19, 2018Valsartan and Hydrochlorothiazide TabletsGCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.Mylan Laboratories Limited, (Nashik FDF) · D-0330-2019Class IIOngoingDec 19, 2018Valsartan and Hydrochlorothiazide TabletsGCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.Mylan Laboratories Limited, (Nashik FDF) · D-0329-2019Class IIOngoingDec 19, 2018Valsartan and Hydrochlorothiazide TabletsGCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.Mylan Laboratories Limited, (Nashik FDF) · D-0328-2019Class IIOngoingDec 19, 2018Valsartan TabletsGCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.Mylan Laboratories Limited, (Nashik FDF) · D-0327-2019Class IIOngoingDec 19, 2018Valsartan TabletsGCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.Mylan Laboratories Limited, (Nashik FDF) · D-0326-2019Class IIOngoingDec 19, 2018Valsartan TabletsGCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.Mylan Laboratories Limited, (Nashik FDF) · D-0325-2019Class IIOngoingDec 19, 2018Valsartan TabletsGCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.Mylan Laboratories Limited, (Nashik FDF) · D-0324-2019Class IIOngoingDec 19, 2018Amlodipine and Valsartan TabletsGCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.Mylan Laboratories Limited, (Nashik FDF) · D-0323-2019Class IIOngoingDec 19, 2018Amlodipine and Valsartan TabletsGCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.Mylan Laboratories Limited, (Nashik FDF) · D-0322-2019Class IIOngoingDec 19, 2018Amlodipine and Valsartan TabletsGCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.Mylan Laboratories Limited, (Nashik FDF) · D-0321-2019Class IIOngoingDec 19, 2018Amlodipine and Valsartan TabletsGCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product.Mylan Laboratories Limited, (Nashik FDF) · D-0320-2019Class IIOngoingDec 19, 2018Amlodipine and Valsartan TabletsCGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.Mylan Pharmaceuticals Inc. · D-0318-2019Class IIOngoingDec 19, 2018Valsartan and Hydrochlorothiazide TabletsCGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.Mylan Pharmaceuticals Inc. · D-0317-2019Class IIOngoingDec 19, 2018Valsartan TabletsCGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.Mylan Pharmaceuticals Inc. · D-0316-2019Class IIOngoingDec 19, 2018Valsartan TabletsCGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product.Mylan Pharmaceuticals Inc. · D-0315-2019

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.